Despite numerous attempts having been made in BC therapy with candidate PDK1 tool compounds, definitive evidence about whether specific inhibitors of PDK1 as monotherapy could achieve favorable results is still lacking; this obliges us to take actions to determine the vulnerabilities of the therapeutic potential in specific PDK1 inhibitors. The gene discussed is PDK1; the disease is breast cancer.